Theorem Clinical Research

Drug Sponsors

Mylan receives approval from India, acquires Agila

Wednesday, September 4, 2013 03:53 PM

Global pharmaceutical company Mylan’s proposed acquisition of the Agila injectables businesses from Indian pharmaceutical company Strides Arcolab has received approval from India's Foreign Investment Promotion Board (FIPB). The transaction also received approval from the Cabinet Committee on Economic Affairs (CCEA). The transaction is expected to close in the fourth quarter of 2013.

More... »


bioMérieux acquires BioFire Diagnostics

Wednesday, September 4, 2013 03:51 PM

bioMérieux, an in vitro diagnostics company, has acquired BioFire Diagnostics, a privately-held U.S.-based company specialized in molecular biology. BioFire invented, manufactures and commercializes its multiplex PCR FilmArray system, a simple and rapid molecular biology solution dedicated to the diagnosis of infectious diseases.

More... »


iPierian to launch True North Therapeutics

Wednesday, September 4, 2013 03:48 PM

iPierian, a biotechnology company developing novel therapies for neurodegenerative disease, has secured financing of $30 million  to continue to advance its drug development in neurodegenerative disease and  to launch a spin-out company, True North Therapeutics.

More... »

Elcelyx Therapeutics spins out NaZura BioHealth

Wednesday, September 4, 2013 03:47 PM

Elcelyx Therapeutics has established NaZura BioHealth, a separate company focusing on development of Gut Sensory Modulators (GSM) including lead product Lovidia, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet, the company’s proprietary delayed-release formulation of metformin for the treatment of patients with type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

More... »

GenVec board restructures operations, withdraws plan of dissolution

Wednesday, September 4, 2013 12:11 PM

The board of directors of GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has withdrawn the Plan of Complete Liquidation and Dissolution for the company, previously adopted May 24.

More... »

Neurotrope completes reverse merger

Wednesday, September 4, 2013 11:58 AM

Nevada-based Neurotrope (formerly BlueFlash Communications) has completed a reverse merger in which Neurotrope BioScience, based in Delaware, became a wholly owned subsidiary of the company.

More... »

Endo to acquire Boca Pharmacal

Friday, August 30, 2013 02:29 PM

Endo Health Solutions, a U.S.-based specialty healthcare company, will acquire privately-held Boca Pharmacal, a specialty generics company, for $225 million in cash. Boca Pharmacal focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids and solutions.

More... »

Meda acquires Acton Pharmaceuticals

Friday, August 30, 2013 02:27 PM

Meda, an international specialty pharmaceutical company, has acquired Acton Pharmaceuticals for $135 million, plus a milestone payment of $10 million and royalties. The acquisition is expected to close during the fourth quarter and is subject to customary closing conditions and U.S. regulatory approval. Existing credit facilities will fund the acquisition.

More... »

Humana, Lilly collaborate to improve healthcare outcomes

Friday, August 30, 2013 02:24 PM

Humana, a Louisville, Ky.-based health and well-being company, and Eli Lilly have signed a multi-year collaboration to improve the healthcare of their members and patients.

More... »

OPKO acquires Prolor Biotech

Friday, August 30, 2013 02:19 PM

OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired Prolor Biotech, a clinical-stage biopharmaceutical company. Stockholders of Prolor will receive 0.9951 shares of OPKO common stock for each share of Prolor common stock. The stockholders of both companies approved all proposals presented at their respective stockholder meetings.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs